These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1339 related articles for article (PubMed ID: 33038433)
1. COVID-19: Discovery, diagnostics and drug development. Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433 [TBL] [Abstract][Full Text] [Related]
2. Lessons learnt from broad-spectrum coronavirus antiviral drug discovery. Bolinger AA; Li J; Xie X; Li H; Zhou J Expert Opin Drug Discov; 2024 Sep; 19(9):1023-1041. PubMed ID: 39078037 [TBL] [Abstract][Full Text] [Related]
3. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
4. Perspectives for repurposing drugs for the coronavirus disease 2019. Cherian SS; Agrawal M; Basu A; Abraham P; Gangakhedkar RR; Bhargava B Indian J Med Res; 2020 Feb & Mar; 151(2 & 3):160-171. PubMed ID: 32317408 [TBL] [Abstract][Full Text] [Related]
5. Current Strategies of Antiviral Drug Discovery for COVID-19. Mei M; Tan X Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887 [TBL] [Abstract][Full Text] [Related]
6. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014 [TBL] [Abstract][Full Text] [Related]
7. The broad-spectrum antiviral recommendations for drug discovery against COVID-19. Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018 [TBL] [Abstract][Full Text] [Related]
8. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406 [TBL] [Abstract][Full Text] [Related]
9. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT mBio; 2021 Jan; 12(1):. PubMed ID: 33468703 [TBL] [Abstract][Full Text] [Related]
10. Emerging strategies on in silico drug development against COVID-19: challenges and opportunities. Yadav M; Dhagat S; Eswari JS Eur J Pharm Sci; 2020 Dec; 155():105522. PubMed ID: 32827661 [TBL] [Abstract][Full Text] [Related]
11. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro. Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455 [TBL] [Abstract][Full Text] [Related]
12. Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. Fenizia C; Galbiati S; Vanetti C; Vago R; Clerici M; Tacchetti C; Daniele T Microbiol Spectr; 2022 Feb; 10(1):e0150421. PubMed ID: 34985303 [TBL] [Abstract][Full Text] [Related]
13. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19. Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136 [TBL] [Abstract][Full Text] [Related]
14. Repurposing Existing Drugs for the Treatment of COVID-19. Farne H; Kumar K; Ritchie AI; Finney LJ; Johnston SL; Singanayagam A Ann Am Thorac Soc; 2020 Oct; 17(10):1186-1194. PubMed ID: 32692580 [TBL] [Abstract][Full Text] [Related]
15. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Froggatt HM; Heaton BE; Heaton NS J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534 [TBL] [Abstract][Full Text] [Related]
16. Drug Discovery Strategies for SARS-CoV-2. Shyr ZA; Gorshkov K; Chen CZ; Zheng W J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801 [TBL] [Abstract][Full Text] [Related]
17. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses. Borbone N; Piccialli G; Roviello GN; Oliviero G Molecules; 2021 Feb; 26(4):. PubMed ID: 33668428 [TBL] [Abstract][Full Text] [Related]
18. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions. Bakowski MA; Beutler N; Wolff KC; Kirkpatrick MG; Chen E; Nguyen TH; Riva L; Shaabani N; Parren M; Ricketts J; Gupta AK; Pan K; Kuo P; Fuller M; Garcia E; Teijaro JR; Yang L; Sahoo D; Chi V; Huang E; Vargas N; Roberts AJ; Das S; Ghosh P; Woods AK; Joseph SB; Hull MV; Schultz PG; Burton DR; Chatterjee AK; McNamara CW; Rogers TF Nat Commun; 2021 Jun; 12(1):3309. PubMed ID: 34083527 [TBL] [Abstract][Full Text] [Related]
19. Drug Discovery of Small Molecules for the Treatment of COVID-19: A Review on Clinical Studies. Goel B; Bhardwaj N; Tripathi N; Jain SK Mini Rev Med Chem; 2021; 21(12):1431-1456. PubMed ID: 33371848 [TBL] [Abstract][Full Text] [Related]